1. Home
  2. LXEH vs AZTR Comparison

LXEH vs AZTR Comparison

Compare LXEH & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LXEH

Lixiang Education Holding Co. Ltd.

N/A

Current Price

$1.83

Market Cap

2.9M

Sector

Real Estate

ML Signal

N/A

Logo Azitra Inc

AZTR

Azitra Inc

N/A

Current Price

$0.14

Market Cap

3.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LXEH
AZTR
Founded
2001
2014
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.5M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
LXEH
AZTR
Price
$1.83
$0.14
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
91.2K
685.2K
Earning Date
05-01-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.10
52 Week High
$3.28
$1.40

Technical Indicators

Market Signals
Indicator
LXEH
AZTR
Relative Strength Index (RSI) 69.96 46.21
Support Level $1.28 $0.12
Resistance Level $2.38 $0.15
Average True Range (ATR) 0.17 0.01
MACD 0.02 0.00
Stochastic Oscillator 47.31 47.14

Price Performance

Historical Comparison
LXEH
AZTR

About LXEH Lixiang Education Holding Co. Ltd.

Lixiang Education Holding Co Ltd is engaged in providing education services, including high school and vocational education services. It offers private basic education at the primary and junior high school levels. The Group has two reportable segments for operations, including high school and vocational education.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: